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http://www.biomedcentral.com/1471-2458/14/41RESEARCH ARTICLE Open AccessInfluenza vaccines and influenza antiviral drugs in
Africa: are they available and do guidelines for
their use exist?
Jazmin Duque1,2*†, Meredith L McMorrow1,3† and Adam L Cohen1,3,4†Abstract
Background: Influenza viruses cause significant morbidity and mortality in Africa, particularly among high-risk
groups, but influenza vaccines and antiviral drugs may not be commonly available and used. The main aim of this
study was to determine the availability and use of influenza vaccines and antiviral drugs as well as to describe
existing related guidelines and policies in Africa.
Methods: A self-administered survey was distributed among key influenza experts in 40 African countries.
Results: Of the 40 countries surveyed, 31 (78%) responded; 14/31 (45%) reported availability of seasonal influenza
vaccine, and 19/31 (65%) reported availability of antiviral drugs for the treatment of influenza. Vaccine coverage
data were only available for 4/14 (29%) countries that reported availability of seasonal influenza vaccine and ranged
from <0.5% to 2% of the population.
Conclusions: Influenza vaccines and antiviral drugs are available in many countries in Africa but coverage estimates
are low and remain largely unknown. Describing the local burden of disease and identifying funding are essential
to encourage countries to use influenza vaccine more widely.
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Influenza is an important contributor to morbidity and
mortality in Africa [1]. Among 15 countries of the African
Network for Influenza Surveillance and Epidemiology
(ANISE), 10% and 22% of inpatient and outpatient res-
piratory cases, respectively, tested positive for influenza
between 2006–2010 [2]. For many years, influenza epide-
miology has been described in countries with temperate
climates like South Africa and Morocco [3,4] but there are
now data that comprehensively describe influenza viru-
ses in tropical countries like Kenya and Zambia [5,6].
In Africa, influenza causes severe illness and deaths in
both temperate and tropical settings [7,8].* Correspondence: jduque@cdc.gov
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stated.Populations in low and middle income countries like
many of those in Africa are more vulnerable to influenza-
related complications because of the high prevalence of
underlying medical conditions and limited access to health
care. For example, outbreaks of influenza A(H3N2), which
circulates widely across the globe, have caused unusually
high case fatality ratios in Madagascar and the Democratic
Republic of Congo [9,10]. In addition, the elderly in South
Africa are four times more likely to die from an influenza
infection than their counterparts in the United States [11].
The high prevalence of comorbidities including human
immunodeficiency virus and tuberculosis contribute to in-
creased influenza-associated mortality in Africa [7].
Vaccination is the most effective way to prevent influ-
enza illness and antiviral drugs help treat viral infection
[12]. Vaccines and antiviral drugs are important particu-
larly among high risk groups such as young children,
pregnant women, the elderly and persons with under-
lying medical conditions. The World Health Organization
(WHO), however, reports that none of the countries inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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fluenza vaccines [13] and that only 2 of the 54 countries
on the continent have access to them [14]. A separate re-
port from the International Federation of Pharmaceutical
Manufacturers states that countries in Africa, the Eastern
Mediterranean and South-East Asia combined receive
only 1% to 4% of the global seasonal influenza vaccine
supply each year [15]. With growing data on the burden
of influenza across the African continent, many countries
are considering introducing or expanding strategies to
prevent and manage influenza infection. We conducted
this study to gather more data on the availability of influ-
enza vaccines and antiviral drugs in Africa as well as re-
lated national policies and guidelines.
Methods
The U.S Centers for Disease Control and Prevention
(CDC) has long-standing relationships with Ministries of
Health, WHO, Institut Pasteur and the U.S. Department
of Defense. We approached these institutions to identify
key in-country influenza experts in Africa who could an-
swer the survey. In addition, La Réunion, a French terri-
tory in the Indian Ocean east of Madagascar, was asked to
participate. Since La Réunion is not a country, their data
were excluded from the country analyses and are pre-
sented separately. This study was considered to be an
evaluation of existing public health programs and not
considered to be public health research.
The survey included 22 questions regarding influenza
vaccines, antiviral drugs and related policies and guide-
lines and was administered in both English and French.
We created an electronic version of this questionnaire
using SurveyMonkey© (SurveyMonkey, Palo Alto, CA)
and collected responses, either electronically or in hard
copy form, from January 2012 through January 2013. Sur-
veys were distributed to representatives from 24 countries
attending the Third Annual ANISE Meeting in Nairobi,
Kenya [16], via email and in person. Data were entered
and analyzed using Microsoft Access© (Microsoft Cor-
poration, Redmond, WA) and OpenEpi [17].
In some cases, more than one person responded per
country. In instances in which survey responses did not
match, the response from the representative from the
Ministry of Health or equivalent was considered valid. If
there was no clear valid response, we tried to determine
a valid response via personal communication with an in-
country influenza expert.
Results
Of the 54 countries on the African continent, we con-
tacted 40 (74%) for this study, of which 31 (78%) com-
pleted the survey. There were 2 or more respondents for
12/31 (39%) of the countries represented. A representa-
tive from La Réunion also completed the survey.Of the 31 countries surveyed, 14 (45%) reported avail-
ability of seasonal influenza vaccine (Figure 1); six in the
private sector only (Democratic Republic of Congo,
Senegal, Togo, Uganda, Zambia, and Zimbabwe) and
eight in both private and public sectors (Cameroon,
Côte d’Ivoire, Egypt, Kenya, Madagascar, Mauritius,
Morocco, and South Africa) (Table 1). Moreover, although
we were not able to find anyone to respond to this survey
in Algeria, WHO reports influenza vaccine is available
there [14]. La Réunion also reported availability of vaccine
in both the private and public sectors.
Regarding the composition of vaccine used, six coun-
tries reported using the Southern Hemisphere vaccine,
four the Northern Hemisphere, and four were unknown.
La Réunion reported using Southern Hemisphere vac-
cine as well (Table 1). Vaccine coverage data were only
available for 4/14 (29%) countries that reported availabil-
ity of seasonal influenza vaccine and ranged from <0.5%
to 2% of the population. Countries that had influenza
vaccine available were from all regions of Africa and
represented all World Bank income classifications, ex-
cept high income as there are no high income countries
in Africa (Table 1) [18]. Of note, vaccine availability was
not associated with World Bank income level (chi-
square = 0.19; p-value = 0.57).
Among the 14 countries that reported having any in-
fluenza vaccine, four (Côte d’Ivoire, Egypt, Mauritius,
and Morocco) reported having a national public policy
for its use; all of them target healthcare workers, young
children, the elderly, and persons with underlying me-
dical conditions. Three target pregnant women and one
pilgrims going to Hajj. South Africa has standing guide-
lines for the prevention and treatment of influenza [19]
but a national public policy regarding vaccination is yet
to be developed.
Nine respondent countries felt national decision-
makers would be willing to introduce vaccine, of which
six (67%) (Angola, Mozambique, Nigeria, Seychelles,
Togo, and Zimbabwe) said the country could do so
within the next 4 years. These same respondents ranked
demonstration of public health burden within the coun-
try and availability of international funding as most im-
portant in influencing decision-makers to introduce and
promote influenza vaccine; evidence that illnesses and
deaths can be prevented by influenza vaccination and
evidence that the national health system will have a
cost-benefit with the introduction of vaccine were still
considered important but did not rank as high.
Of the 31 respondent countries, 23 (74%) reported re-
ceiving and/or purchasing pandemic influenza vaccine in
or after 2009, and 19 (83%) of these reported using these
vaccines. Four countries (Kenya, Mali, Senegal and South
Africa) and La Réunion reported conducting influenza
vaccine research in the years 2012 and/or 2013.
Figure 1 Availability of influenza vaccine and antiviral drugs in Africa.
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ported availability of antiviral drugs for the treatment of
influenza; nine in both the public and private sector, six
in the public sector only and four in the private sector
only (Table 1). La Réunion also reported availability of
antiviral drugs in both the private and public sectors.
Cameroon, Egypt, Ghana and South Africa reported
having national guidelines for the use of these anti-
viral drugs.
Discussion and conclusions
Influenza vaccines and antivirals are available in Africa
although population coverage is estimated to be very
low. Vaccines and antivirals are available in the private
sector alone or both private and public sectors. The
Southern Hemisphere formulation is most widely used
in Africa despite lower production worldwide [13]. Over
the last few years, the Northern and Southern hemisphere
influenza vaccine formulations have been identical albeit
the time in which these vaccines are distributed is differ-
ent. Several countries that do not currently have influenza
vaccine available are likely to consider doing so in the nextfew years and would use national burden estimates to
inform policy. However, funding is a concern. As has
been seen globally with other underutilized vaccines
[20], many of the countries in Africa without influ-
enza vaccine are low income. The Global Alliance for
Vaccines and Immunisation (GAVI) is a public-private
partnership that aids low income countries in procur-
ing vaccines. Currently, there are 56 countries eligible
to receive GAVI support and 35 of these countries are in
Africa [21].
Before the 2009 influenza A(H1N1) pandemic, most
countries in Africa had inadequate data on the burden
of influenza disease and high risk groups to inform influ-
enza public health policies [22]. Since then, influenza
surveillance systems have been strengthened and many
countries are studying influenza incidence and seasona-
lity, particularly among sub-groups [1,2]. Networks like
ANISE [2] and AfriFlu [23] have increased the scientific
dialogue among influenza experts in Africa.
Globally, one of the main concerns is whether seasonal
influenza vaccine supply is adequate to meet the needs
of all countries for future pandemics [13,24,25]. A survey
Table 1 Availability of influenza vaccine and antiviral drugs for the treatment of influenza in Africa*












Angola South Upper middle No -- -- No --
Burkina Faso West Low No -- -- No --
Cameroon Central Lower-middle Yes Both Southern Yes Public
Cape Verde West Lower-middle No -- -- No --
Comoros Indian Ocean Low No -- -- No --
Côte d’Ivoire West Lower-middle Yes Both Northern Yes Public
Democratic Republic of Congo Central Low Yes Private Northern No --
Djibouti East Lower-middle No -- -- Yes Public
Egypt North Lower-middle Yes Both Unknown Yes Both
Ethiopia East Low No -- -- No --
Ghana West Lower-middle No -- -- Yes Public
Kenya East Low Yes Both Southern Yes Private
Madagascar Indian Ocean Low Yes Both Southern Yes Both
Malawi South Low No -- -- No --
Mali Central Low No -- -- No --
Mauritius Indian Ocean Upper-middle Yes Both Southern Yes Both
Morocco North Lower-middle Yes Both Northern Yes Both
Mozambique South Low No -- -- Yes Private
Namibia South Upper-middle No -- -- No --
Niger Central Low No -- -- No --
Nigeria West Lower-middle No -- -- Yes Public
Republic of Congo Central Lower-middle No -- -- Yes Both
Réunion (France) Indian Ocean NA Yes Both Southern Yes Both
Senegal West Lower-middle Yes Private Northern No --
Seychelles Indian Ocean Upper-middle No -- -- Yes Public
Sierra Leone West Low No -- -- No --
South Africa South Upper-middle Yes Both Southern Yes Both
Tanzania East Low No -- -- Yes Both
Togo West Low Yes Private Unknown Yes Both
Uganda East Low Yes Private Southern Yes Private
Zambia South Lower-middle Yes Private Unknown Yes Private
Zimbabwe South Low Yes Private Unknown Yes Both
*This table includes La Réunion (a French territory in the Indian Ocean) in addition to 31 African countries.
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pandemics are likely to emerge, found seasonal influenza
vaccine sales in the private sector average <1000 doses
per 100,000 population and guidelines for vaccine use in
only half of these countries [20]. In contrast, 5/15 (33%)
of the African countries with influenza vaccine reported
having national guidelines for influenza vaccines. Invest-
ment in influenza research to promote evidence-based
influenza public health policies in Africa is essential to
encouraging policy development and implementation.
The main limitation of this study is that these findings,
albeit reported by credible sources, may not accuratelyreflect the true vaccine and antiviral use in Africa, espe-
cially since we were unable contact representatives in 14
countries and did not get a response from 9 countries,
many of which are lower income. It is very difficult in
many of these countries, for example, to ascertain vac-
cine coverage rates and to understand vaccine supply.
While vaccines may be available, distribution and use by
high risk groups remains unknown. Given that such a
small proportion (1%-4%) of the global seasonal vaccine
supply is distributed in Africa, the Middle East, and
Southeast Asia [15], and since most of the world’s popu-
lation lives in these areas, vaccination rates must be low.
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disease in Africa, the identification of groups at risk of
serious complications must be met with increasing avail-
ability of vaccines, policies targeting identified risk groups,
and funding to support larger scale procurement and dis-
tribution efforts in resource-poor countries.
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